Logo image of FBLG

FIBROBIOLOGICS INC (FBLG) Stock Fundamental Analysis

NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD

0.6569  +0 (+0.05%)

Fundamental Rating

0

Overall FBLG gets a fundamental rating of 0 out of 10. We evaluated FBLG against 556 industry peers in the Biotechnology industry. FBLG has a bad profitability rating. Also its financial health evaluation is rather negative. FBLG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FBLG had negative earnings in the past year.
FBLG had a negative operating cash flow in the past year.
FBLG Yearly Net Income VS EBIT VS OCF VS FCFFBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -67.87%, FBLG is doing worse than 62.77% of the companies in the same industry.
FBLG has a worse Return On Equity (-408.08%) than 75.72% of its industry peers.
Industry RankSector Rank
ROA -67.87%
ROE -408.08%
ROIC N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FBLG Yearly ROA, ROE, ROICFBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FBLG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBLG Yearly Profit, Operating, Gross MarginsFBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, FBLG has more shares outstanding
Compared to 1 year ago, FBLG has a worse debt to assets ratio.
FBLG Yearly Shares OutstandingFBLG Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
FBLG Yearly Total Debt VS Total AssetsFBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -4.57, we must say that FBLG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FBLG (-4.57) is comparable to the rest of the industry.
A Debt/Equity ratio of 3.35 is on the high side and indicates that FBLG has dependencies on debt financing.
FBLG has a Debt to Equity ratio of 3.35. This is amonst the worse of the industry: FBLG underperforms 82.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.35
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACCN/A
FBLG Yearly LT Debt VS Equity VS FCFFBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

A Current Ratio of 1.12 indicates that FBLG should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.12, FBLG is doing worse than 86.15% of the companies in the same industry.
A Quick Ratio of 1.12 indicates that FBLG should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.12, FBLG is not doing good in the industry: 85.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
FBLG Yearly Current Assets VS Current LiabilitesFBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.71% over the past year.
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FBLG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.58% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.62%
EPS Next 2Y-20.05%
EPS Next 3Y-6.22%
EPS Next 5Y-12.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBLG Yearly Revenue VS EstimatesFBLG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M 400M
FBLG Yearly EPS VS EstimatesFBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBLG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBLG Price Earnings VS Forward Price EarningsFBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBLG Per share dataFBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as FBLG's earnings are expected to decrease with -6.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.05%
EPS Next 3Y-6.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBLG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROBIOLOGICS INC

NASDAQ:FBLG (7/25/2025, 9:32:32 AM)

0.6569

+0 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)N/A N/A
Inst Owners16.86%
Inst Owner Change-0.49%
Ins Owners15.82%
Ins Owner Change0.33%
Market Cap25.13M
Analysts82.22
Price Target10.88 (1556.26%)
Short Float %2.5%
Short Ratio2.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.32%
Min EPS beat(2)1.96%
Max EPS beat(2)88.69%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.77%
PT rev (3m)-16.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.19
P/tB 9.19
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.87%
ROE -408.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 3.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -4.57
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.52%
EPS Next Y-31.62%
EPS Next 2Y-20.05%
EPS Next 3Y-6.22%
EPS Next 5Y-12.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-75.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.92%
OCF growth 3YN/A
OCF growth 5YN/A